RedHill Biopharma (NASDAQ:RDHL) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of RedHill Biopharma (NASDAQ:RDHLGet Free Report) in a report released on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Trading Down 2.6 %

NASDAQ:RDHL opened at $3.18 on Wednesday. RedHill Biopharma has a 1-year low of $3.01 and a 1-year high of $20.28. The company’s fifty day moving average price is $5.68 and its 200-day moving average price is $8.56.

Institutional Trading of RedHill Biopharma

An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC acquired a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHLFree Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned approximately 0.40% of RedHill Biopharma as of its most recent SEC filing. 7.20% of the stock is owned by institutional investors and hedge funds.

RedHill Biopharma Company Profile

(Get Free Report)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.

Further Reading

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.